ESC 2022 preview – who’s got the XI factor?
Bristol Myers Squibb/Johnson & Johnson and Bayer will soon get more hints about whether their Eliquis and Xarelto follow-ons can cut it.
Pfizer bets $5.4bn against gene therapies in sickle cell
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
ISTH 2022 – Sanofi faces more fitusiran doubts
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
